TY - JOUR
T1 - Cardiovascular oncology
T2 - Exploring the effects of targeted cancer therapies on atherosclerosis
AU - Seijkens, Tom T.P.
AU - Lutgens, Esther
N1 - Funding Information:
This work was supported by the Netherlands Heart Institute (Young@Heart grant to T.T.P.S.), Amsterdam Cardiovascular Sciences (MD/PhD grant to T.T.P.S.), The Netherlands CardioVascular Research Initiative: the Dutch Heart Foundation, Dutch Federation of University Medical Centers, the Netherlands, Organization for Health Research and Development, and the Royal Netherlands Academy of Sciences for the GENIUS-II project ‘Generating the best evidence-based pharmaceutical targets for atherosclerosis-II’ (CVON2018–19). This study was also supported by the Netherlands Organization for Scientific Research (NWO) (VICI grant 016.130.676 to E.L.), the EU (H2020-PHC-2015–667673, REPROGRAM to E.L.), the European Research Council (ERC consolidator grant CD40-INN 681492 to E.L.), and the German Science Foundation (DFG, CRC1123, project A5).
Publisher Copyright:
© 2018 Lippincott Williams and Wilkins. All rights reserved.
PY - 2018/10/1
Y1 - 2018/10/1
N2 - Purpose of review Targeted cancer therapies have revolutionized the treatment of cancer in the past decade, but cardiovascular toxicity is a rising problem in cancer patients. Here we discuss the effects of targeted cancer therapies on atherosclerosis. Increasing the awareness of these adverse effects will promote the development of evidence-based preventive strategies in the emerging field of cardiovascular oncology. Recent findings Vascular endothelial growth factor inhibitors, immunomodulatory imide drugs, tyrosine kinase inhibitors and immune checkpoint inhibitors are successfully used as treatment for many types of solid and hematologic malignancies. However, clinical and experimental studies have demonstrated that these drugs can drive atherosclerosis, thereby causing adverse cardiovascular events such as myocardial infarction, stroke and peripheral arterial occlusive diseases. Summary In this review, we discuss how on-target and off-target effects of novel cancer drugs may affect atherosclerosis and we postulate how these cardiovascular adverse events can be prevented in the future.
AB - Purpose of review Targeted cancer therapies have revolutionized the treatment of cancer in the past decade, but cardiovascular toxicity is a rising problem in cancer patients. Here we discuss the effects of targeted cancer therapies on atherosclerosis. Increasing the awareness of these adverse effects will promote the development of evidence-based preventive strategies in the emerging field of cardiovascular oncology. Recent findings Vascular endothelial growth factor inhibitors, immunomodulatory imide drugs, tyrosine kinase inhibitors and immune checkpoint inhibitors are successfully used as treatment for many types of solid and hematologic malignancies. However, clinical and experimental studies have demonstrated that these drugs can drive atherosclerosis, thereby causing adverse cardiovascular events such as myocardial infarction, stroke and peripheral arterial occlusive diseases. Summary In this review, we discuss how on-target and off-target effects of novel cancer drugs may affect atherosclerosis and we postulate how these cardiovascular adverse events can be prevented in the future.
KW - Atherosclerosis
KW - Cancer
KW - Cardiovascular oncology
KW - Targeted cancer therapies
UR - http://www.scopus.com/inward/record.url?scp=85069597372&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85069597372&partnerID=8YFLogxK
U2 - 10.1097/MOL.0000000000000538
DO - 10.1097/MOL.0000000000000538
M3 - Article
C2 - 30074493
AN - SCOPUS:85069597372
SN - 0957-9672
VL - 29
SP - 381
EP - 388
JO - Current opinion in lipidology
JF - Current opinion in lipidology
IS - 5
ER -